Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $51.8050, but opened at $47.00. Zealand Pharma A/S shares last traded at $46.30, with a volume of 718 shares traded.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ZLDPF shares. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, Zacks Research lowered shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Zealand Pharma A/S Trading Down 6.1%

The firm has a market capitalization of $3.31 billion, a P/E ratio of 7.68 and a beta of 0.88. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $46.90 and a 200-day moving average of $48.19.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.